What question did this study set out to answer?

To examine the prevalence and implications of biologic dose escalation in patients with inflammatory bowel disease.

March 2, 2026

Biologic dose escalation in inflammatory bowel disease in the United States

Puntos clave

To examine the prevalence and implications of biologic dose escalation in patients with inflammatory bowel disease.
Analyzed patient data on biologic therapy use
Assessed dose escalation frequency
Evaluated associated healthcare costs
One-third of patients escalated their biologic dose
Significant increase in disease-related healthcare costs
Identified challenges in managing long-term biologic therapy in IBD

Resumen

Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.

Biologic dose escalation in inflammatory bowel disease in the United States

Puntos clave

Resumen

Cite This Study

Also Consider

Also Consider